Tag: malignancies

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome...

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsMalignancies

New Diversified Monthly Income Strategy for SMSF Trustees June 2026 Update – TermPlus Launches High-Yield Fixed-Term Accounts

B.A.S.S., Pro Football Hall of Fame announce landmark partnership, Celebrity Pro-Am Tournament on St. Lawrence River

Corgi Insurance and Silicon Valley Bank Partner to Connect Clients to Preferred Coverage Solutions

Tag: malignancies

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome...

CD5 Targeted Therapies CD5 Targeting CAR T Cell Therapy Clinical Trials Market Insight 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us